TY  - GEN
AB  - The increased production of reactive oxygen species (ROS) is a hallmark of fibrosis and  cancer. In fibrosis, the release of ROS along  with secretion of pro-fibrotic cytokines by  the  immune  cells  during  the  inflammatory  phase  has  been  known  to  promote  the  activation  of  fibroblasts  and  induce  collagen  deposition.  In  cancer,  ROS  also  plays  a  crucial  role  in  various  signaling  cascades  involved  in  cellular  survival,  proliferation,  resistance to apoptosis, angiogenesis, as well as metastasis. However, the results from  clinical  studies  involving  antioxidant  therapies  in  patients  have  been  disappointing,  mostly due to the low bioavailability of the conventional antioxidant therapies.
AD  - Oregon Health and Science University
AU  - Morry, Jingga
DA  - 2016
DO  - 10.6083/M4PV6JGT
DO  - DOI
ED  - Yantasee, Wassana
ED  - Advisor
ID  - 3029
KW  - Fibrosis
KW  - Breast Neoplasms
KW  - Neoplasms
KW  - Reactive Oxygen Species
KW  - Neoplasm Metastasis
KW  - Silicates
KW  - sirna
KW  - antioxidant
KW  - breast cancer
KW  - mesoporous
L1  - https://digitalcollections.ohsu.edu/record/3029/files/3842_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/3029/files/3842_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/3029/files/3842_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/3029/files/3842_etd.pdf
N2  - The increased production of reactive oxygen species (ROS) is a hallmark of fibrosis and  cancer. In fibrosis, the release of ROS along  with secretion of pro-fibrotic cytokines by  the  immune  cells  during  the  inflammatory  phase  has  been  known  to  promote  the  activation  of  fibroblasts  and  induce  collagen  deposition.  In  cancer,  ROS  also  plays  a  crucial  role  in  various  signaling  cascades  involved  in  cellular  survival,  proliferation,  resistance to apoptosis, angiogenesis, as well as metastasis. However, the results from  clinical  studies  involving  antioxidant  therapies  in  patients  have  been  disappointing,  mostly due to the low bioavailability of the conventional antioxidant therapies.
PB  - Oregon Health and Science University
PY  - 2016
T1  - Exploiting the antioxidant potential and siRNA delivery function of mesoporous silica nanoparticles for the treatment of skin fibrosis and breast cancer metastasis
TI  - Exploiting the antioxidant potential and siRNA delivery function of mesoporous silica nanoparticles for the treatment of skin fibrosis and breast cancer metastasis
UR  - https://digitalcollections.ohsu.edu/record/3029/files/3842_etd.pdf
Y1  - 2016
ER  -